WEBULL
WebtradeDownload

How Investors Are Reacting To Genmab (CPSE:GMAB) Epcoritamab’s Phase 3 Overall-Survival Miss in DLBCL

Simply Wall St · 2d ago
  • In July 2026, Genmab A/S and AbbVie clarified that the Phase 3 EPCORE DLBCL-1 trial of epcoritamab in relapsed or refractory diffuse large B-cell lymphoma did not achieve a statistically significant improvement in overall survival, the sole primary endpoint in the United States.
  • This clarification highlights the complexity of region-specific trial endpoints and leaves investors waiting for detailed peer-reviewed data to understand epcoritamab’s broader clinical profile.
  • We’ll now examine how the lack of a US overall-survival benefit for epcoritamab reshapes Genmab’s investment narrative and future outlook.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Genmab Investment Narrative Recap

To own Genmab, you need to believe its antibody platforms and partnered oncology portfolio can translate into durable, diversified cash flows despite clinical and regulatory setbacks. The US overall-survival miss for epcoritamab in EPCORE DLBCL-1 is a setback for that specific indication, but it does not appear to alter Genmab’s near term financial guidance or the central risk that pipeline execution missteps could weaken long term earnings resilience.

The most relevant recent announcement is the European Commission approval of TEPKINLY (epcoritamab) plus R2 for relapsed or refractory follicular lymphoma. This decision underlines that epcoritamab’s value is not tied to a single DLBCL endpoint, and it supports the current catalyst of expanding labeled uses across B cell malignancies, even as investors reassess how the DLBCL-1 outcome might influence future regulatory and reimbursement discussions.

Yet this EPCORE DLBCL-1 result also underscores a risk investors should be aware of around Genmab’s dependence on a focused oncology pipeline and...

Read the full narrative on Genmab (it's free!)

Genmab's narrative projects $6.2 billion revenue and $1.6 billion earnings by 2029. This requires 16.8% yearly revenue growth and roughly a $0.8 billion earnings increase from $821.0 million today.

Uncover how Genmab's forecasts yield a DKK2392 fair value, a 29% upside to its current price.

Exploring Other Perspectives

CPSE:GMAB 1-Year Stock Price Chart
CPSE:GMAB 1-Year Stock Price Chart

Before this setback, the most optimistic analysts were assuming revenue could reach about US$7.3 billion and earnings US$2.3 billion by 2029, which is far more bullish than the baseline view and could be tested by how you weigh this latest epcoritamab data against Genmab’s concentrated oncology risks.

Explore 7 other fair value estimates on Genmab - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.